首页> 外文期刊>AACN advanced critical care >Pharmacological management of pulmonary arterial hypertension
【24h】

Pharmacological management of pulmonary arterial hypertension

机译:肺动脉高压的药理管理

获取原文
获取原文并翻译 | 示例
           

摘要

Pulmonary hypertension (PH) is a complex disorder that was first described in a case report as "pulmonary vascular sclerosis" in 1891 by German internist Dr Ernst von Romberg. Without treatment, it is a progressive, fatal disease that is characterized by elevated pulmonary arterial pressure and secondary right ventricular failure. According to the most recent evidence from a national French registry, the prevalence of pulmonary arterial hypertension (PAH) is about 15 cases per 1 million adult inhabitants with an incidence of 2.4 cases per 1 million adult inhabitants. According to a registry that evaluates early and long-term PAH disease management, the prevalence of PAH in the United States is 12.4 cases per million and the incidence is 2.3 cases per million.3 Unfortunately, not all cases of PAH are reported to the registries, so both the prevalence and incidence data are considered low estimates.
机译:肺动脉高压(PH)是一种复杂的疾病,在1891年的一例病例报告中,德国内科医生Ernst von Romberg博士首次将其描述为“肺血管硬化”。未经治疗,它是一种进行性致命疾病,其特征是肺动脉压升高和继发性右心衰竭。根据法国国家注册中心的最新证据,肺动脉高压(PAH)的患病率约为每100万成年居民15例,每100万成年居民中2.4例的发生率。根据评估早期和长期PAH疾病管理的注册管理机构的数据,在美国,PAH的流行率为12.4百万分之一,发病率为2.3百万分之三。3不幸的是,并非所有PAH病例都报告给注册管理机构,因此患病率和发病率数据均被视为低估算值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号